North America In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review Board (PMPRB)—amendments related to new excessive price factors. The decision, well-received by Innovative Medicines Canada, came after these controversial economic…
Canada Pamela C. Fralick, President of Innovative Medicines Canada (IMC), the innovative pharma association in Canada, looks back on her first half year in position, the challenges of navigating Canada’s complex and multifaceted health ecosystem, and her goal of bringing together all healthcare stakeholders in much-needed dialogue on how to improve…
See our Cookie Privacy Policy Here